Who are Sustained-release oral dalfampridine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Firdapse, DALFAMPRIDINE, SR-fampridine, TEV-48125, 3,4-diaminopyridine, TETA 4HCL (60-<W108).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sustained-release-oral-dalfampridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Sustained-release oral dalfampridine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sustained-release oral dalfampridine (Sustained-release oral dalfampridine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel blocker. Area: Neurology.

marketed Potassium channel blocker Voltage-gated potassium channels (Kv channels) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Sustained-release oral dalfampridine (Sustained-release oral dalfampridine) — Sheba Medical Center. Dalfampridine is a potassium channel blocker that enhances action potential conduction in demyelinated nerve fibers by prolonging the duration of the action potential.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sustained-release oral dalfampridine TARGET	Sustained-release oral dalfampridine	Sheba Medical Center	marketed	Potassium channel blocker	Voltage-gated potassium channels (Kv channels)
Firdapse	AMIFAMPRIDINE	Catalyst Pharms	marketed	Potassium Channel Blocker	Voltage-gated potassium channel	2018-01-01
DALFAMPRIDINE	DALFAMPRIDINE		marketed	Potassium Channel Blocker [EPC]		2010-01-01
SR-fampridine	SR-fampridine	University of Southern Denmark	marketed	Potassium channel blocker	Voltage-gated potassium channels
TEV-48125	TEV-48125	Otsuka Pharmaceutical Co., Ltd.	phase 3	sodium-activated potassium channel blocker	Nav1.5
3,4-diaminopyridine	3,4-diaminopyridine	Oregon Health and Science University	phase 3	Potassium channel blocker	Voltage-gated potassium channels
TETA 4HCL (60-<W108)	TETA 4HCL (60-<W108)	Orphalan	phase 3	Potassium channel blocker	Potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel blocker class)

Orphalan · 3 drugs in this class
Biogen · 2 drugs in this class
Essentialis, Inc. · 1 drug in this class
National Center for Research Resources (NCRR) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sheba Medical Center · 1 drug in this class
University of Southern Denmark · 1 drug in this class
D'Youville College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sustained-release oral dalfampridine — Competitive Intelligence Brief. https://druglandscape.com/ci/sustained-release-oral-dalfampridine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab